This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-12. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Unlike graphene, which is a two-dimensional semimetal, carbon nanotubes are either metallic or semiconducting along the tubular axis. For a given (n,m) nanotube, if n = m, the nanotube is metallic; if n − m is a multiple of 3 and n ≠ m, then the nanotube is quasi-metallic with a very small band gap, otherwise the nanotube is a moderate semiconductor. Thus, all armchair (n = m) nanotubes are metallic, and nanotubes (6,4), (9,1), etc. are semiconducting. Carbon nanotubes are not semimetallic because the degenerate point (the point where the π [bonding] band meets the π* [anti-bonding] band, at which the energy goes to zero) is slightly shifted away from the K point in the Brillouin zone because of the curvature of the tube surface, causing hybridization between the σ* and π* anti-bonding bands, modifying the band dispersion. The rule regarding metallic versus semiconductor behavior has exceptions because curvature effects in small-diameter tubes can strongly influence electrical properties. Thus, a (5,0) SWCNT that should be semiconducting in fact is metallic according to the calculations. Likewise, zigzag and chiral SWCNTs with small diameters that should be metallic have a finite gap (armchair nanotubes remain metallic). In theory, metallic nanotubes can carry an electric current density of 4 billion A/cm2, which is more than 1,000 times greater than those of metals such as copper, where for copper interconnects, current densities are limited by electromigration.
=== 27 June === In Donetsk Oblast, two people were killed by Russian shelling in Kurakhove, while one person was killed in a separate attack in Toretsk. The Ukrainian military claimed to have driven out Russian forces from the Kanal neighborhood of Chasiv Yar. Russian media reported that an explosion occurred at a chemical plant in Tver Oblast following a drone strike. The plant is believed to manufacture aviation fuel. According to local residents four drones struck the plant, damaging a workshop, pipeline and roof. No casualties were reported and Russian authorities claimed all four drones were destroyed.
== Specialty areas == Many medical laboratory scientists are generalists, skilled in most areas of the clinical laboratory. However, some are specialists, qualified by unique undergraduate education or additional training to perform more complex analyses than usual within a specific field. Specialties include clinical biochemistry, hematology, coagulation, microbiology, bacteriology, toxicology, virology, parasitology, mycology, immunology, immunohematology (blood bank), histopathology, histocompatibility, cytopathology, genetics, cytogenetics, electron microscopy, and IVF labs. Medical technologists specialty may use additional credentials, such as "SBB" (specialist in blood banking), "SM" (specialist in microbiology), "SC" (specialist in chemistry), or "SH" (specialist in hematology) from the American Society for Clinical Pathology (ASCP). These additional notations may be appended to the base credential, for example, "MLS (ASCP), SBB (ASCP)". Additional information can be found in the ASCP Procedures for Examination & Certification. Andrology laboratory scientist (such as those working for a sperm bank), embryology laboratory scientist, and molecular diagnostics technologist certifications are provided by the American Association of Bioanalysts; those with the certifications are classified as ALS (AAB), ELS (AAB), and MDxT (AAB), respectively.
Sources: en.wikipedia.org
In November 2020, Hetero signed an agreement with the Russian Direct Investment Fund (RDIF) to manufacture more than 100 million doses of Sputnik V, the world’s first registered COVID-19 vaccine. Hetero continued its response to COVID-19 with the launch of Movfor (molnupiravir) in late 2021 and Nirmacom (a generic version of nirmatrelvir-ritonavir) in 2022. In December 2022, Nirmacom became the first generic adaptation of the COVID treatment to receive WHO prequalification, allowing Hetero to distribute it to 95 LMICs under a voluntary license administered through the Medicines Patent Pool. 2023- Present In 2023, Hetero celebrated 30 years of its journey from a small-time API producer to a global pharmaceutical manufacturing powerhouse. In 2024, Hetero entered a partnership with Gilead Sciences to expand availability of Lenacapavir, a long acting injectable HIV treatment, across 120 high-incidence countries in order to support the global HIV response. In 2025, Hetero opened a new commercial office in Warsaw, Poland, marking the company’s formal entry into the Eastern European pharmaceutical markets. In 2026, Hetero launched generic versions of semaglutide - the active ingredient in medicines for type 2 diabetes and obesity management- in emerging markets under the names Truglyx, Rolmodl, and Moto G.
This work hinged on his demonstration that red blood cell glutathione was unstable to oxidative stress. Later, he was to develop an assay for glutathione that was widely used in studies of red cell oxidative metabolism. He was later transferred to Camp Detrick in Frederick, Maryland (1954–1955), where he studied Q fever. He was honorably discharged from the Army with the rank of captain. Beutler then joined the faculty of the Department of Medicine at the University of Chicago, where he studied iron metabolism and red blood cell metabolism. In 1959, he became chairman of the Department of Medicine of the City of Hope National Medical Center in Duarte, California, and in 1979 assumed the chairmanship of the Department of Clinical Research at the Scripps Clinic and Research Foundation. Three years later, he was asked to become Chairman of a merged department (the Department of Molecular and Experimental Medicine) at Scripps, which later became The Scripps Research Institute in La Jolla, CA. He maintained his position as Chairman until his 80th birthday, only a few days before his death. Not long after moving to California, Beutler made one of his most important contributions. A new colleague at the City of Hope and ultimately a lifelong friend, Susumu Ohno had recently demonstrated that the histologically observable Barr body present in the nuclei of mammalian female cells was a hyperchromatic X chromosome. Beutler immediately recognized that this might account for the variable expression of X-linked genes in females heterozygous for X-linked mutations.
==== Anabolic ==== Bone marrow stimulation: For decades, AAS were the mainstay of therapy for hypoplastic anemias due to leukemia, kidney failure or aplastic anemia. Growth stimulation: AAS can be used by pediatric endocrinologists to treat children with growth failure. However, the availability of recombinant growth hormone, which has fewer side effects, makes this a secondary treatment. Stimulation of appetite and preservation and increase of muscle mass: AAS have been given to people with chronic wasting conditions such as cancer and AIDS. Stimulation of lean body mass and prevention of bone loss in elderly men, as some studies indicate. However, a 2006 placebo-controlled trial of low-dose testosterone supplementation in elderly men with low levels of testosterone found no benefit on body composition, physical performance, insulin sensitivity, or quality of life. Prevention or treatment of osteoporosis in postmenopausal women. Nandrolone decanoate is approved for this use. Although they have been indicated for this treatment, AAS saw little use for this purpose due to their virilizing side effects. Aiding weight gain following surgery or physical trauma, during chronic infection, or in the context of unexplained weight loss. Counteracting the catabolic effect of long-term corticosteroid therapy. Oxandrolone improves both short-term and long-term outcomes in people recovering from severe burns, and is well-established as a safe treatment for this indication. Treatment of idiopathic short stature, hereditary angioedema, alcoholic hepatitis, and hypogonadism.
Sources: en.wikipedia.org
=== Syndesmotic tear === The severity of acute syndesmosis injury is rated from grade I to III by several authors. A grade I injury is a partial anteroinferior tibiofibular ligament tear, meaning the exorotation and squeeze tests are negative for this grade. Grade II injury is a complete anteroinferior tibiofibular ligament and inferior interosseous ligament tear, meaning that squeeze test and exorotation are positive. This results in the injury being stabilized with immobilization but not operatively stabilized. A grade III injury is a complete anteroinferior tibiofibular ligament tear including a (partial) interosseous ligament tear and deltoid ligament avulsion, meaning the joint is unstable and positive on the exorotation and squeeze tests. This grade requires operative stabilization. If the syndesmosis is torn apart as result of bone fracture, surgeons will sometimes fix the relevant bones together with a syndesmotic screw, temporarily replacing the syndesmosis, or with a tightrope fixation, which is called syndesmosis procedure. The screw inhibits normal movement of the bones and, thereby, the corresponding joint(s). When the natural articulation is healed, the screw may be removed. The tightrope fixation with elastic fiberwire suture on the other hand allows physiologic motion of the ankle and may be permanent.
=== Oxidative stress === Oxidative stress causes the accumulation of reactive oxygen species (ROS), resulting in oxidative damage to DNA, proteins involved in cellular repair, and lipids that support the skin barrier. Oxidative stress can hinder the fibroblasts' collagen production, endothelial cell angiogenesis, and keratinocytes' re-epithelialization. The result of oxidative stress is a state of cellular senescence, where cells secrete pro-inflammatory factors and are unable to divide. Senescent cells signal to immune cells, perpetuating a non-resolving wound that can develop into an ulcer.
=== Reception === Underworld has a 30% overall approval rating on film-critics' aggregate site Rotten Tomatoes based on 161 reviews, with an average rating of 4.8/10. The site's consensus reads, "Though stylish to look at, Underworld is tedious and derivative." Metacritic, which uses a weighted average, assigned the film a score of 42 out of 100, based on 34 critics, indicating "mixed or average" reviews. Audiences polled by CinemaScore gave the film an average grade of "B+" on an A+ to F scale. Roger Ebert said, "This is a movie so paltry in its characters and shallow in its story that the war seems to exist primarily to provide graphic visuals". However, some critics were more favorable: the New York Daily News praised it as being "stylish and cruel, and mightily entertaining for certain covens out there". Salon reviewer Andrew O'Hehir gave a mixed review, stating, "by any reasonable standard, this dark vampire epic — all massive overacting, cologne-commercial design and sexy cat suits — sucks," but that "at least it gives a crap", conceding that despite the movie's flaws, the complex vampire-werewolf mythology backstory "has been meticulously worked out". The film has since developed a strong cult following.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.